Protalix BioTherapeutics (PLX) Cash from Operations (2010 - 2026)

Protalix BioTherapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 22025000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 535.45% year-over-year to 22025000.0 in Q1 2026; TTM through Mar 2026 was 15090000.0, a 2738.11% increase from a year earlier, with the FY2025 full-year figure at 11993000.0, down 238.26% from the prior year.
• Cash from Operations grew to 22025000.0 in Q1 2026 per PLX's latest filing, from 2030000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 22025000.0 in Q1 2026 and bottomed at 9204000.0 in Q3 2022.
• The 5-year median for Cash from Operations is 2998000.0 (2023), against an average of 447764.71.
• Across the five-year window, Cash from Operations plunged 389.57% in 2022 and surged 535.45% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 2611000.0 in 2022, then soared by 237.69% to 3595000.0 in 2023, then gained by 11.02% to 3991000.0 in 2024, then slumped by 49.14% to 2030000.0 in 2025, then surged by 984.98% to 22025000.0 in 2026.
• Per Business Quant, the three latest PLX Cash from Operations figures stand at 22025000.0 (Q1 2026), 2030000.0 (Q4 2025), and 3732000.0 (Q3 2025).